Risk factors for oral mucositis in paediatric oncology patients receiving alkylant chemotherapy

被引：23
作者：
Fadda G. [1 ,2 ]
Campus G. [1 ]
Lugliè P. [1 ]
机构：
[1] Dental Institute, University of Sassari, I-07100 Sassari
[2] Institut Gustave Roussy, Paris
来源：
BMC Oral Health | / 6卷 / 1期
关键词：
Autologous Stem Cell Transplantation; Oral Mucositis; Busulfan; Nephroblastoma; Common Toxicity Criterion;
D O I：
10.1186/1472-6831-6-13
中图分类号：
学科分类号：
摘要：
Background: We describe the risk indicators for oral mucositis (OM) in paediatric oncology patients hospitalised in the Institut Gustave Roussy (Villejuif-Paris) and treated with alkylant chemotherapy with autologous peripheral blood progenitor cells. Methods: The sample was selected using PIGAS software. Three groups of subjects received different chemotherapy regimens: A. Melphalan, B. Busulfan and C. other alkylant protocols. The degree of mucositis was recorded by CTC version 2.0 (Common Toxicity Criteria). Descriptive statistics were performed. The association between mucositis and risk indicator variables was tested using a χ2 test. The association between case status and covariates was tested using unconditional logistic regression analysis. Results: Of the 337 children enrolled, 241 showed mucositis (group 1) and 96 did not show mucositis (group 2) during alkylant chemotherapy. There was a higher prevalence of male patients in both groups. The three different chemotherapy regimen groups are correlated with the appearance of oral mucositis (χ2 = 22.42, p < 0.01). Weight loss was higher in group 1 (χ2 = 6.31, p = 0.01). The duration of aplasia was lower in the Busulfan protocol (7.5 days) than in the Melphalan group (9.3 days) or the other regimens (8.6 days). The use of Bufulfan® was directly associated with case status (presence of oral mucositis): odds ratio [OR] = 2.1 and confidence interval [95%CI] = 1.3-3.0. Also, occurrences of germinal tumours and secondary bacterial infections were directly linked with case status: [OR] = 1.4 and 1.8, confidence interval [95%CI] = 1.2 - 1.7 and 1.1 - 2.5, respectively. Conclusion: The presence of OM was associated with the three different chemotherapy regimens considered; in particularly patients treated with Busulfan had the highest prevalence. © 2006 Fadda et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 25 条
[1]  
Raber-Durlacher J.E., Epstein J.B., Bresters D., Stern-Zivan L., Oral complications in children with cancer, Eur J Paediatric Dent, 3, pp. 3-12, (2005)
[2]  
Szpirglas H., Deszcz-Thomas A., Lacoste J.P., Chemiothérapie des cancers, Encycl Méd Chir Stomatologie, pp. 22-65, (1997)
[3]  
Wojtaszek C., Management of chemotherapy-induced stomatitis, Clinical Journal of Oncology Nursing, 4, pp. 263-270, (2000)
[4]  
Wardley A.M., Jayson G.C., Swindell R., Morgenstern G.R., Chang J., Bloor R., Fraser C.J., Scarffe J.H., Prospective evaluation of oral mucositis in patient receiving myeloablative conditioning regimens and haemopoietic progenitor rescue, Brit J Haematol, 110, pp. 292-299, (2000)
[5]  
Squier C.A., Kremer M.J., Biology of oral mucosa and esophagus, J National Cancer Inst Monographs, 29, pp. 7-15, (2001)
[6]  
Barasch A., Peterson D.E., Risk factors for ulcerative oral mucositis in cancer patients: Unanswered questions, Oral Oncol, 39, pp. 91-100, (2003)
[7]  
Sonis S.T., Mucositis as a biological process: A new hypothesis for the development of chemotherapy-induced stomatoxicity, Oral Oncol, 34, pp. 39-43, (1998)
[8]  
Reference Guidelines (ESMO), (2005)
[9]  
Wartelle M., Kramar A., Jan P., PIGAS. An interactive statistical database management system, Proceedings of the Second National Workshop on Statistical Database Management, pp. 124-132, (1983)
[10]  
(2004)
123